Literature DB >> 22349439

A molecular mechanism underlying ovarian dysfunction of polycystic ovary syndrome: hyperandrogenism induces epigenetic alterations in the granulosa cells.

Fan Qu1, Fang-Fang Wang, Rong Yin, Guo-Lian Ding, Mohamed El-Prince, Qian Gao, Bi-Wei Shi, Hui-Hui Pan, Yi-Ting Huang, Min Jin, Peter C K Leung, Jian-Zhong Sheng, He-Feng Huang.   

Abstract

The objective of this study was to explore whether hyperandrogenism induces epigenetic alterations of peroxisome proliferator-activated receptor gamma 1 (PPARG1), nuclear corepressor 1 (NCOR1), and histone deacetylase 3 (HDAC3) genes in granulosa cells (GCs) of polycystic ovary syndrome (PCOS) women and whether these alterations are involved in the ovarian dysfunction induced by hyperandrogenism. Thirty-two infertile PCOS women and 147 infertile women with tubal blockage were recruited. PCOS women were divided into the hyperandrogenism (HA) PCOS group (n = 13) and nonhyperandrogenism (N-HA) PCOS group (n = 19). Sixty female Sprague-Dawley rats were used for PCOS model establishment. In GCs of HA PCOS women, PPARG1 mRNA expression was lower, whereas NCOR1 and HDAC3 mRNA expression were higher than N-HA PCOS women and controls (P < 0.05). When all women were divided into successful and failed pregnancy subgroups according to the following clinical pregnancy outcome, we found lower PPARG1 mRNA levels and higher NCOR1 and HDAC3 mRNA levels in the failed subgroup of HA PCOS (P < 0.05). Two hypermethylated CpG sites in the PPARG1 promoter and five hypomethylated CpG sites in the NCOR1 promoter were observed only in HA PCOS women (P < 0.01 to P < 0.0005). The acetylation levels of histone H3 at lysine 9 and p21 mRNA expression were decreased in human GCs treated with dihydrotestosterone in vitro (P < 0.05). PCOS rat models also showed alterations of PPARG1, NCOR1, and HDAC3 mRNA expression and methylation changes of PPARG1 and NCOR1, consistent with the results from humans. Hyperandrogenism induces the epigenetic alterations of PPARG1, NCOR1, and HDAC3 in GCs, which are involved in the ovarian dysfunction of HA PCOS.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22349439     DOI: 10.1007/s00109-012-0881-4

Source DB:  PubMed          Journal:  J Mol Med (Berl)        ISSN: 0946-2716            Impact factor:   4.599


  29 in total

1.  Serum anti-Mullerian hormone as a surrogate for antral follicle count for definition of the polycystic ovary syndrome.

Authors:  P Pigny; S Jonard; Y Robert; D Dewailly
Journal:  J Clin Endocrinol Metab       Date:  2005-12-20       Impact factor: 5.958

2.  A modified and improved method for bisulphite based cytosine methylation analysis.

Authors:  A Olek; J Oswald; J Walter
Journal:  Nucleic Acids Res       Date:  1996-12-15       Impact factor: 16.971

3.  Optimal use of hormone determinations in the biochemical diagnosis of the polycystic ovary syndrome.

Authors:  P Koskinen; T A Penttilä; L Anttila; R Erkkola; K Irjala
Journal:  Fertil Steril       Date:  1996-03       Impact factor: 7.329

4.  Effects of testosterone on cancellous bone, marrow adipocytes, and ovarian phenotype in a young female rat model of polycystic ovary syndrome.

Authors:  Nozomi Tamura; Takumi Kurabayashi; Hiroshi Nagata; Hiroshi Matsushita; Tetsuro Yahata; Kenichi Tanaka
Journal:  Fertil Steril       Date:  2005-10       Impact factor: 7.329

5.  Altered aquaporin expression in women with polycystic ovary syndrome: hyperandrogenism in follicular fluid inhibits aquaporin-9 in granulosa cells through the phosphatidylinositol 3-kinase pathway.

Authors:  Fan Qu; Fang-Fang Wang; Xiu-E Lu; Min-Yue Dong; Jian-Zhong Sheng; Ping-Ping Lv; Guo-Lian Ding; Bi-Wei Shi; Dan Zhang; He-Feng Huang
Journal:  Hum Reprod       Date:  2010-04-08       Impact factor: 6.918

6.  Steroidogenic alterations and adrenal androgen excess in PCOS.

Authors:  Suhail A R Doi; Mona Al-Zaid; Philip A Towers; Christopher J Scott; Kamal A S Al-Shoumer
Journal:  Steroids       Date:  2006-06-16       Impact factor: 2.668

Review 7.  Polycystic ovary syndrome: etiology, pathogenesis and diagnosis.

Authors:  Mark O Goodarzi; Daniel A Dumesic; Gregorio Chazenbalk; Ricardo Azziz
Journal:  Nat Rev Endocrinol       Date:  2011-01-25       Impact factor: 43.330

8.  Effects of rosiglitazone in obese women with polycystic ovary syndrome and severe insulin resistance.

Authors:  Vicken Sepilian; Manubai Nagamani
Journal:  J Clin Endocrinol Metab       Date:  2004-10-13       Impact factor: 5.958

9.  Regulation of bovine tumor necrosis factor-alpha-induced protein 6 in ovarian follicles during the ovulatory process and promoter activation in granulosa cells.

Authors:  Khampoune Sayasith; Nadine Bouchard; Monique Doré; Jean Sirois
Journal:  Endocrinology       Date:  2008-08-07       Impact factor: 4.736

Review 10.  Polycystic ovary syndrome and its developmental origins.

Authors:  Daniel A Dumesic; David H Abbott; Vasantha Padmanabhan
Journal:  Rev Endocr Metab Disord       Date:  2007-06       Impact factor: 6.514

View more
  42 in total

1.  Epigenetic regulation of traf2- and Nck-interacting kinase (TNIK) in polycystic ovary syndrome.

Authors:  Da Li; Jiao Jiao; Yi-Ming Zhou; Xiu-Xia Wang
Journal:  Am J Transl Res       Date:  2015-06-15       Impact factor: 4.060

2.  Placental imprinting variation associated with assisted reproductive technologies and subfertility.

Authors:  Julia F Litzky; Maya A Deyssenroth; Todd M Everson; David A Armstrong; Luca Lambertini; Jia Chen; Carmen J Marsit
Journal:  Epigenetics       Date:  2017-06-16       Impact factor: 4.528

3.  Alternative splicing of the androgen receptor in polycystic ovary syndrome.

Authors:  Fangfang Wang; Jiexue Pan; Ye Liu; Qing Meng; Pingping Lv; Fan Qu; Guo-Lian Ding; Christian Klausen; Peter C K Leung; Hsiao Chang Chan; Weimiao Yao; Cai-Yun Zhou; Biwei Shi; Junyu Zhang; Jianzhong Sheng; Hefeng Huang
Journal:  Proc Natl Acad Sci U S A       Date:  2015-03-30       Impact factor: 11.205

Review 4.  Epigenetically regulated imprinted gene expression associated with IVF and infertility: possible influence of prenatal stress and depression.

Authors:  Julia F Litzky; Carmen J Marsit
Journal:  J Assist Reprod Genet       Date:  2019-05-24       Impact factor: 3.412

Review 5.  Intrauterine environment and polycystic ovary syndrome.

Authors:  Daniel A Dumesic; Mark O Goodarzi; Gregorio D Chazenbalk; David H Abbott
Journal:  Semin Reprod Med       Date:  2014-04-08       Impact factor: 1.303

6.  Developmental Programming: Contribution of Epigenetic Enzymes to Antral Follicular Defects in the Sheep Model of PCOS.

Authors:  Xingzi Guo; Muraly Puttabyatappa; Robert C Thompson; Vasantha Padmanabhan
Journal:  Endocrinology       Date:  2019-10-01       Impact factor: 4.736

7.  DNA methylation in promoter regions of genes involved in the reproductive and metabolic function of children born to women with PCOS.

Authors:  Bárbara Echiburú; Fermín Milagro; Nicolás Crisosto; Francisco Pérez-Bravo; Cristian Flores; Ana Arpón; Francisca Salas-Pérez; Sergio E Recabarren; Teresa Sir-Petermann; Manuel Maliqueo
Journal:  Epigenetics       Date:  2020-04-20       Impact factor: 4.528

8.  Cellular and exosome mediated molecular defense mechanism in bovine granulosa cells exposed to oxidative stress.

Authors:  Mohammed Saeed-Zidane; Lea Linden; Dessie Salilew-Wondim; Eva Held; Christiane Neuhoff; Ernst Tholen; Michael Hoelker; Karl Schellander; Dawit Tesfaye
Journal:  PLoS One       Date:  2017-11-08       Impact factor: 3.240

9.  Transcutaneous electrical acupoint stimulation alleviates the hyperandrogenism of polycystic ovarian syndrome rats by regulating the expression of P450arom and CTGF in the ovaries.

Authors:  Fan Qu; Yi Liang; Jue Zhou; Rui-Jie Ma; Jie Zhou; Fang-Fang Wang; Yan Wu; Jian-Qiao Fang
Journal:  Int J Clin Exp Med       Date:  2015-05-15

10.  Metabolic actions of insulin in ovarian granulosa cells were unaffected by hyperandrogenism.

Authors:  Shidou Zhao; Haijing Xu; Yuqian Cui; Wenting Wang; Yingying Qin; Li You; Wai-Yee Chan; Yun Sun; Zi-Jiang Chen
Journal:  Endocrine       Date:  2016-04-08       Impact factor: 3.633

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.